192 related articles for article (PubMed ID: 38422464)
1. Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.
Awidi A; Alzu'bi M; Odeh N; Alrawabdeh J; Al Zyoud M; Hamadneh Y; Bawa'neh H; Magableh A; Alshorman A; Al-Fararjeh F; Aladily T; Zeidan AM
JCO Glob Oncol; 2024 Feb; 10():e2300281. PubMed ID: 38422464
[TBL] [Abstract][Full Text] [Related]
2. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
3. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
4. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
6. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
7. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Hayashi T; Miyanishi K; Sato Y; Takimoto R; Kato J
Int J Hematol; 2012 May; 95(5):527-34. PubMed ID: 22407873
[TBL] [Abstract][Full Text] [Related]
10. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
12. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
Babushok DV; Bessler M; Olson TS
Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
[TBL] [Abstract][Full Text] [Related]
13. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
14. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
16. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
[TBL] [Abstract][Full Text] [Related]
18. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
[TBL] [Abstract][Full Text] [Related]
20. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]